Winnow Wealth LLC Takes $862,000 Position in Insulet Corporation $PODD

Winnow Wealth LLC acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,789 shares of the medical instruments supplier’s stock, valued at approximately $862,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. True Wealth Design LLC lifted its position in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the period. Golden State Wealth Management LLC increased its stake in Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after purchasing an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in Insulet during the second quarter worth $35,000. Whittier Trust Co. of Nevada Inc. raised its holdings in Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares during the last quarter. Finally, Quent Capital LLC purchased a new stake in Insulet during the third quarter worth $49,000.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $255.81 on Friday. The company has a market cap of $18.00 billion, a P/E ratio of 74.15, a P/E/G ratio of 1.42 and a beta of 1.40. The business has a fifty day simple moving average of $291.55 and a 200-day simple moving average of $308.99. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $354.88. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The firm had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period last year, the company earned $1.08 EPS. The firm’s quarterly revenue was up 29.9% on a year-over-year basis. Equities research analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. Stifel Nicolaus started coverage on Insulet in a research report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 price target for the company. Barclays raised their target price on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Zacks Research downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Wolfe Research raised their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Finally, BTIG Research lifted their price objective on Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday, November 21st. Twenty equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $375.05.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.